Literature DB >> 20963329

Clinical aspects of hemolysis in patients with P. vivax malaria treated with primaquine, in the Brazilian Amazon.

Wilson M Ramos Júnior1, José F J Sardinha, Mônica R F Costa, Marli S Santana, Maria G C Alecrim, Marcus V G Lacerda.   

Abstract

This report describes the development of hemolysis in eighteen glucose-6-phosphate dehydrogenase deficient patients treated for Plasmodium vivax malaria with chloroquine and primaquine. The most frequent findings accompanying hemolysis were fever and leukocytosis, in addition to anemia requiring red blood cell transfusion, and development of acute renal failure. Hemolysis in patients using primaquine is not infrequent and contributes to the morbidity of infection caused by Plasmodium vivax.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20963329     DOI： 10.1590/s1413-86702010000400017

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN： 1413-8670            Impact factor:   1.949


  23 in total

Review 1.  Malaria-related anaemia: a Latin American perspective.

Authors:  Juan Pablo Quintero; André Machado Siqueira; Alberto Tobón; Silvia Blair; Alberto Moreno; Myriam Arévalo-Herrera; Marcus Vinícius Guimarães Lacerda; Sócrates Herrera Valencia
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

2.  Malaria in selected non-Amazonian countries of Latin America.

Authors:  Myriam Arevalo-Herrera; Martha Lucia Quiñones; Carlos Guerra; Nora Céspedes; Sandra Giron; Martha Ahumada; Juan Gabriel Piñeros; Norma Padilla; Zilka Terrientes; Angel Rosas; Julio Cesar Padilla; Ananias A Escalante; John C Beier; Socrates Herrera
Journal:  Acta Trop       Date:  2011-07-01       Impact factor: 3.112

Review 3.  Primaquine in vivax malaria: an update and review on management issues.

Authors:  Deepika Fernando; Chaturaka Rodrigo; Senaka Rajapakse
Journal:  Malar J       Date:  2011-12-12       Impact factor: 2.979

4.  PharmGKB summary: very important pharmacogene information for G6PD.

Authors:  Ellen M McDonagh; Caroline F Thorn; José M Bautista; Ilan Youngster; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-03       Impact factor: 2.089

5.  The reality of using primaquine.

Authors:  Kathy L Burgoine; Germana Bancone; François Nosten
Journal:  Malar J       Date:  2010-12-27       Impact factor: 2.979

Review 6.  Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature.

Authors:  Marcus V G Lacerda; Maria P G Mourão; Márcia A A Alexandre; André M Siqueira; Belisa M L Magalhães; Flor E Martinez-Espinosa; Franklin S Santana Filho; Patrícia Brasil; Ana M R S Ventura; Mauro S Tada; Vanja S C D Couto; Antônio R Silva; Rita S U Silva; Maria G C Alecrim
Journal:  Malar J       Date:  2012-01-09       Impact factor: 2.979

7.  Risk factors and characterization of Plasmodium vivax-associated admissions to pediatric intensive care units in the Brazilian Amazon.

Authors:  Ellen Fátima Caetano Lança; Belisa Maria Lopes Magalhães; Sheila Vitor-Silva; André Machado Siqueira; Silvana Gomes Benzecry; Márcia Almeida Araújo Alexandre; Connor O'Brien; Quique Bassat; Marcus Vinícius Guimarães Lacerda
Journal:  PLoS One       Date:  2012-04-16       Impact factor: 3.240

Review 8.  Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.

Authors:  Senaka Rajapakse; Chaturaka Rodrigo; Sumadhya Deepika Fernando
Journal:  Cochrane Database Syst Rev       Date:  2015-04-29

9.  Malaria control and elimination in Sri Lanka: documenting progress and success factors in a conflict setting.

Authors:  Rabindra R Abeyasinghe; Gawrie N L Galappaththy; Cara Smith Gueye; James G Kahn; Richard G A Feachem
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

10.  Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.

Authors:  Chaturaka Rodrigo; Senaka Rajapakse; Deepika Fernando
Journal:  Cochrane Database Syst Rev       Date:  2020-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.